Emily joined Novartis in 2019. She has over 20 years of experience in drug substance and drug product manufacturing and supporting roles in the biologics, gene therapy, and regenerative medicine space. Previous roles also include managing third party suppliers, facility start-up, and CMC support.

Emily holds a bachelor’s degree in Microbiology from University of Maryland at College Park, MD, USA and an MBA from North Carolina State University, NC, USA.